Compare · CTKB vs WAT
CTKB vs WAT
Side-by-side comparison of Cytek Biosciences Inc. (CTKB) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTKB and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $43.64B, about 62.1x CTKB ($703.2M).
- Over the past year, CTKB is up 32.8% and WAT is up 30.6% - CTKB leads by 2.3 points.
- WAT has been more active in the news (4 items in the past 4 weeks vs 2 for CTKB).
- WAT has more recent analyst coverage (25 ratings vs 13 for CTKB).
- Company
- Cytek Biosciences Inc.
- Waters Corporation
- Price
- -
- -
- Market cap
- $703.2M
- $43.64B
- 1M return
- +1.15%
- +1.57%
- 1Y return
- +32.83%
- +30.56%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 1995
- News (4w)
- 2
- 4
- Recent ratings
- 13
- 25
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest CTKB
- SEC Form 8-K filed by Cytek Biosciences Inc.
- Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
- Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
- Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Cytek Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
- PRESIDENT AND CEO Jiang Wenbin converted options into 120,095 shares and covered exercise/tax liability with 36,269 shares, increasing direct ownership by 2% to 5,561,029 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mccombe William D. converted options into 35,420 shares and covered exercise/tax liability with 11,904 shares, increasing direct ownership by 21% to 134,693 units (SEC Form 4) to satisfy withholding tax
- Director Muir Glenn P converted options into 3,086 shares (SEC Form 4)
Latest WAT
- Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
- Director Knight Heather was granted 57 shares, increasing direct ownership by 4% to 1,338 units (SEC Form 4)
- Director Jiang Wei was granted 57 shares, increasing direct ownership by 2% to 3,630 units (SEC Form 4)
- Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
- Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
- Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
- UBS resumed coverage on Waters with a new price target
- SEC Form 3 filed by new insider Wu Tong (Nmn)
- Waters upgraded by Piper Sandler with a new price target
- Waters Corporation to Present at the Wells Fargo Healthcare Conference